Amphiphilic Semisynthetic Triterpenoids Impair Survival Pathways and Suppress Clonogenic Growth in Multidrug-Resistant High-Risk Neuroblastoma
Silvana Alfei, Cinzia Domenicotti, Sara Tirendi, Elaheh Khaledizadeh, Dafni Graikioti, Constantinos M. Athanassopoulos, Guendalina Zuccari, Caterina Reggio, Barbara Marengo · 2026
Read Amphiphilic Semisynthetic Triterpenoids Impair Survival Pathways and Suppress Clonogenic Growth in Multidrug-Resistant High-Risk Neuroblastoma by Silvana Alfei, Cinzia Domenicotti, Sara Tirendi, Elaheh Khaledizadeh, Dafni Graikioti, Constantinos M. Athanassopoulos, Guendalina Zuccari, Caterina Reggio, Barbara Marengo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13466524.txt.
Description
Silvana Alfei and colleagues test lab-made variants of three tree bark compounds against a stubborn childhood nerve tumor, in a 2026 study. High-risk neuroblastoma often learns to resist standard drugs, so new chemistry is needed. Seven modified compounds built from betulin, betulinic acid, and ursolic acid were compared with their natural parents and with a standard chemotherapy drug.
Several variants formed tiny bubbles in water and carried strong positive charge, traits that favor entering cells. Most derivatives killed tumor cells better than their natural sources and better than the standard drug, especially in a drug-resistant cell line. One ursolic acid derivative stood out as the most active, weakening survival pathways and stopping colony growth.
Catalog record
| CREATOR | Silvana Alfei, Cinzia Domenicotti, Sara Tirendi, Elaheh Khaledizadeh, Dafni Graikioti, Constantinos M. Athanassopoulos, Guendalina Zuccari, Caterina Reggio, Barbara Marengo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |